14 citations
,
August 2021 in “Molecular Genetics and Metabolism Reports” Pegvaliase effectively reduces blood phenylalanine levels in most PKU patients, but requires personalized plans and good communication to manage side effects.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
November 2005 in “PubMed”
April 2016 in “The Journal of Sexual Medicine” Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
February 2026 in “European Urology”
20 citations
,
December 2016 in “Neurodegenerative disease management” Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
January 2021 in “Asian Journal of Pharmaceutical and Clinical Research” FT-Raman spectroscopy is effective for identifying drug polymorphs, ensuring quality and stability.
13 citations
,
November 2014 in “Toxicology Letters” Finasteride affects UGT1A4 enzyme, but not enough to cause issues when combined with other drugs.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
5 citations
,
May 2018 in “European journal of pharmacology” Fesoterodine is effective and safe for elderly patients with overactive bladder.
January 2011 in “Bloomsbury Academic eBooks”
5 citations
,
January 2021 in “Dermatology Online Journal” An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.
March 2016 in “International Journal of Infectious Diseases” Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
October 2024 in “Internal Medicine” Stopping nalfurafine reversed hair loss in a hemodialysis patient.
July 2025 in “The Journal of Dermatology” Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.
November 2023 in “Journal of Skin and Sexually Transmitted Diseases” Gefitinib can cause scalp skin issues and permanent hair loss.
June 2017 in “Journal of The American Academy of Dermatology” Teriflunomide often causes mild to moderate hair thinning and loss in MS patients, which usually improves with or without treatment.
4 citations
,
January 1996 in “PubMed” November 2022 in “International Journal of Trichology” Finasteride can cause rare but serious skin rashes.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
May 2024 in “Reactions weekly”
5 citations
,
January 2021 in “Inflammatory Bowel Diseases” Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
1 citations
,
October 2023 in “Journal of the Endocrine Society” HIV medication ritonavir can increase the effects of nasal sprays like fluticasone, causing Cushing's syndrome.
32 citations
,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
6 citations
,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.